EPIGENOMICS N Helden (Seite 1693)
eröffnet am 24.08.06 16:40:24 von
neuester Beitrag 26.04.24 05:43:08 von
neuester Beitrag 26.04.24 05:43:08 von
Beiträge: 52.366
ID: 1.078.825
ID: 1.078.825
Aufrufe heute: 0
Gesamt: 8.314.759
Gesamt: 8.314.759
Aktive User: 0
ISIN: DE000A37FT41 · WKN: A37FT4
1,5800
EUR
-2,92 %
-0,0475 EUR
Letzter Kurs 29.04.24 Lang & Schwarz
Neuigkeiten
14.03.24 · wO Newsflash  |
14.03.24 · wO Newsflash |
14.03.24 · EQS Group AG |
15.02.24 · EQS Group AG |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 25,28 | +72,56 | |
| 4,7450 | +35,57 | |
| 5,0200 | +26,13 | |
| 8,9900 | +22,31 | |
| 0,6650 | +19,82 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6050 | -18,24 | |
| 6,5500 | -19,14 | |
| 3,9900 | -21,30 | |
| 2,3100 | -25,00 | |
| 7,2800 | -59,58 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 53.890.778 von TheDude335 am 14.12.16 12:11:52
auch toll, da ist jedes unternehmen auf den social media seiten heutzutage und epi nutzt dieses medium absolut nicht....auch auf twitter nichts zu finden......tolle ir arbeit, oder??!
das kostet nicht mal etwas!!!
aber epi hats ja nicht notwendig...
fb....
doch gibt es....doch die seite besteht aus genau nichts.....auch toll, da ist jedes unternehmen auf den social media seiten heutzutage und epi nutzt dieses medium absolut nicht....auch auf twitter nichts zu finden......tolle ir arbeit, oder??!
das kostet nicht mal etwas!!!
aber epi hats ja nicht notwendig...
Bin per Zufall auf den Auftritt von Epi bei Facebook (USA) gestoßen. Finde ich in der deutschen Suchmaske von Facebook nicht..
https://www.facebook.com/epigenomics/
https://www.facebook.com/epigenomics/
Grosser Nachfrage-Order werden bei Epi immer bedient! Das ist Gesetz!
Antwort auf Beitrag Nr.: 53.890.424 von Paluru am 14.12.16 11:37:01ich hoffe, du stehst aber nach wie vor zu deiner Chartanalyse von vor 2 Wochen. Damit müsste der Kurs heute wieder über den langfristigen Abwärtstrend (blaue Linie) zurückkommen (knapp über 4,50). Oder gibst du deine Prognose hiermit auf ?
Und da war sie wieder: die medigene101-Körbchen-Strategie-Chance.
Bin gespannt, ob die 3,99€ auch noch getroffen werden.
Gruß+Dank
Paluru
Bin gespannt, ob die 3,99€ auch noch getroffen werden.
Gruß+Dank
Paluru
Trading Spotlight
Antwort auf Beitrag Nr.: 53.889.944 von DewDiligence am 14.12.16 10:42:14
Moderator: The next question comes from Marietta Miemietz, Equinet. Please go ahead with your question.
14:42
Marietta Miemietz: I was going to ask a couple of questions, please. The first one is on international distribution partnerships and how your thinking has evolved there, because I always thought of it as a pretty long shot, but you announced broad Southeast Asia partnerships, so can you just elaborate a little bit how that came about, what the terms are, what sort of revenues your partner is targeting, and also to what extent we should be expecting some deals in the near to medium term? And then secondly I just wanted to follow up on Tim's questions on the presidential election and the political situation in the US, so, it's great to hear you're not really expecting any reimbursement challenges, and in fact my sense is that actually David... Donald Trump is fairly favourable to drugs and...diagnostics, but I would be quite keen to hear your views on the mechanisms of any potential impact on reimbursement for Epi proColon that could come from his repealing of Obamacare, because I mean that was, I think, a very important promise during his campaign, but wasn't very clear to me what exactly Obamacare would get replaced with just from a very mechanistic angle, so that'd be really, really helpful. Thank you very much.
16:00
Greg Hamilton: Okay. So thank you, and thank you for your questions. In regards to distribution, we were introduced to the partner in Southeast Asia, they actually are a distributor for a very, very large molecular diagnostics company as well based in the US, so they have experience in the market, we thought they were a very good fit for Epi proColon, and we do not disclose anticipated volumes or pricing with our distributors, but they are very enthusiastic about the opportunity in those four markets, and, you know, based on that enthusiasm and their projections of what they can do in those markets, we felt it was a very good opportunity to sign a distribution agreement. For other international markets we are looking at other potential distribution partners, the reality is, based on our size we are not gonna be able to cover every market globally with this product, and we are gonna have to utilise partners. So we will look opportunistically across the globe and identify those partners. In key markets such as China we have already done that with BioChain, and we will continue to do that. So that will be an important part of our growth strategy as we go forward. In regards to Donald Trump winning the election, you know, like most people across the globe I think America is absorbing it because it was not anticipated in any way, shape or form, but the reality is, I think, you know, after, you know, today where you have that unexpected result affecting the worldwide
markets, you know, as we see with any major event, you know, over a relatively short period of time the market calms down and stabilises, which we fully expect. In regards to Obamacare, we do not see the repealing of Obamacare really affecting our business. I think most experts and myself, you know, included, I think the repealing of Obamacare is not necessarily a wholesale discarding of Obamacare, but in essence fixing the major issues with Obamacare, and I think some of the components of Obamacare will remain. But regardless, when you look at our product, we are FDA-approved for the unscreened market, and it would be hard to find anyone who thinks it's a good idea for the unscreened market to remain and for us to not introduce new technology to try and get 23 million people screened for a cancer that ultimately shouldn't exist if people followed screening protocols. So we feel very confident that, you know, our technology and our product ultimately align very well with, you know, all aspects of healthcare in regards to, you know, getting people screened, getting rid of this disease and ultimately lowering cost.
19:20
Marietta Miemietz: Okay, great, thank you very much.
Analystin Marietta Mimietz von Equinet...
...hatte diese Fragen im Q3 an Hamilton gestellt. Daraus kann ich mir die aktuelle Herabstufung auf Neutral, 4,81 nicht zusammenreimen. Hat jemand die Analyse, die die Einschätzung untermauert? Oder ist das nur so einen Meldung aus dem Off?Moderator: The next question comes from Marietta Miemietz, Equinet. Please go ahead with your question.
14:42
Marietta Miemietz: I was going to ask a couple of questions, please. The first one is on international distribution partnerships and how your thinking has evolved there, because I always thought of it as a pretty long shot, but you announced broad Southeast Asia partnerships, so can you just elaborate a little bit how that came about, what the terms are, what sort of revenues your partner is targeting, and also to what extent we should be expecting some deals in the near to medium term? And then secondly I just wanted to follow up on Tim's questions on the presidential election and the political situation in the US, so, it's great to hear you're not really expecting any reimbursement challenges, and in fact my sense is that actually David... Donald Trump is fairly favourable to drugs and...diagnostics, but I would be quite keen to hear your views on the mechanisms of any potential impact on reimbursement for Epi proColon that could come from his repealing of Obamacare, because I mean that was, I think, a very important promise during his campaign, but wasn't very clear to me what exactly Obamacare would get replaced with just from a very mechanistic angle, so that'd be really, really helpful. Thank you very much.
16:00
Greg Hamilton: Okay. So thank you, and thank you for your questions. In regards to distribution, we were introduced to the partner in Southeast Asia, they actually are a distributor for a very, very large molecular diagnostics company as well based in the US, so they have experience in the market, we thought they were a very good fit for Epi proColon, and we do not disclose anticipated volumes or pricing with our distributors, but they are very enthusiastic about the opportunity in those four markets, and, you know, based on that enthusiasm and their projections of what they can do in those markets, we felt it was a very good opportunity to sign a distribution agreement. For other international markets we are looking at other potential distribution partners, the reality is, based on our size we are not gonna be able to cover every market globally with this product, and we are gonna have to utilise partners. So we will look opportunistically across the globe and identify those partners. In key markets such as China we have already done that with BioChain, and we will continue to do that. So that will be an important part of our growth strategy as we go forward. In regards to Donald Trump winning the election, you know, like most people across the globe I think America is absorbing it because it was not anticipated in any way, shape or form, but the reality is, I think, you know, after, you know, today where you have that unexpected result affecting the worldwide
markets, you know, as we see with any major event, you know, over a relatively short period of time the market calms down and stabilises, which we fully expect. In regards to Obamacare, we do not see the repealing of Obamacare really affecting our business. I think most experts and myself, you know, included, I think the repealing of Obamacare is not necessarily a wholesale discarding of Obamacare, but in essence fixing the major issues with Obamacare, and I think some of the components of Obamacare will remain. But regardless, when you look at our product, we are FDA-approved for the unscreened market, and it would be hard to find anyone who thinks it's a good idea for the unscreened market to remain and for us to not introduce new technology to try and get 23 million people screened for a cancer that ultimately shouldn't exist if people followed screening protocols. So we feel very confident that, you know, our technology and our product ultimately align very well with, you know, all aspects of healthcare in regards to, you know, getting people screened, getting rid of this disease and ultimately lowering cost.
19:20
Marietta Miemietz: Okay, great, thank you very much.
und ich bin gespannt, ob nun diese chinesischen Neuinvestoren sich bei diesem Kurslevel am Markt bedienen.
Antwort auf Beitrag Nr.: 53.889.944 von DewDiligence am 14.12.16 10:42:14wenn so eine Analystenbude so eine Studie mit dann Empfehlungen und Zielkursen ausspricht, dann haben die auch mit dem CEO gesprochen. Also hat deren Statement schon einen gewissen Aussagewert.
Wie bewertet ihr die Verteilung der Umsätze auf die Börsenplätze? Heute geht fast alles über XETRA und Tradegate. An anderen Tagen geht auch mal viel z.B. auf dem Börsenplatz Stuttgart. XETRA & Tradegate eher ausländische (=China?!), Stuttgart eher deutsche Investoren?! Kann man daraus eventuell Interessen herausleiten oder bin ich komplett auf dem Holzweg? Was meint ihr?
Antwort auf Beitrag Nr.: 53.890.028 von stefan25 am 14.12.16 10:49:02sehe es genau so.vieleicht ist der ceo stumm,oder das unternehmen ist wirklich nichts wert.vieleicht wird die klitsche aber auch zur übernahme bereit geschossen den china kauft ja im moment jede technik die sie kriegen können.das gute daran wäre, der ceo mus dann gehen samt seiner unfähigen vorstandskollegen.
Durchsuchen
14.03.24 · wO Newsflash · Epigenomics |
14.03.24 · EQS Group AG · Epigenomics |
15.02.24 · EQS Group AG · Epigenomics |
31.01.24 · EQS Group AG · Epigenomics |
26.01.24 · EQS Group AG · Epigenomics |